BRAF in melanoma: current strategies and future directions.


Journal Article (Review)

Selective BRAF inhibitors have now been established as a standard of care option for patients diagnosed with metastatic melanoma whose tumors carry a BRAF mutation. Their successful development represents a milestone in the treatment of this disease, and has the potential to impact therapy for other malignancies as well. The use of these agents, however, has introduced a number of critical questions about the optimal use and selection of patients for BRAF inhibitor therapy. This review discusses the current status of BRAF inhibitor clinical development, the clinicopathologic features of BRAF-mutated melanoma, as well as strategies for overcoming resistance.

Full Text

Duke Authors

Cited Authors

  • Salama, AKS; Flaherty, KT

Published Date

  • August 15, 2013

Published In

Volume / Issue

  • 19 / 16

Start / End Page

  • 4326 - 4334

PubMed ID

  • 23770823

Pubmed Central ID

  • 23770823

International Standard Serial Number (ISSN)

  • 1078-0432

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.CCR-13-0779


  • eng

Conference Location

  • United States